

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/077,283	02/14/2002	Matthias Rath	11957/20	3317
26646	7590 09/14/2005		EXAMINER	
KENYON & KENYON			MARX, IRENE	
ONE BROADWAY NEW YORK, NY 10004			ART UNIT	PAPER NUMBER
	•		1651	
			DATE MAIL ED: 00/14/200	•

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Advisory Action	10/077,283	RATH, MATTHIAS				
Before the Filing of an Appeal Brief	Examiner	Art Unit				
	Irene Marx	1651				
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence address				
THE REPLY FILED 29 August 2005 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.						
 The reply was filed after a final rejection, but prior to filin applicant must timely file one of the following replies: (1) application in condition for allowance; (2) a Notice of Application (RCE) in compliance time periods: a) The period for reply expiresmonths from the mailing of the period for reply expires	an amendment, affidavit, or other peal (with appeal fee) in compliance with 37 CFR 1.114. The reply mu	evidence, which places the e with 37 CFR 41.31; or (3) a				
b) The period for reply expires on: (1) the mailing date of this Adv	_	e final rejection, whichever is later. In no				
event, however, will the statutory period for reply expire later the Examiner Note: If box 1 is checked, check either box (a) or (b) MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f	ONLY CHECK BOX (b) WHEN THE FI					
Extensions of time may be obtained under 37 CFR 1.136(a). The date on been filed is the date for purposes of determining the period of extension a CFR 1.17(a) is calculated from: (1) the expiration date of the shortened stabove, if checked. Any reply received by the Office later than three month earned patent term adjustment. See 37 CFR 1.704(b).	which the petition under 37 CFR 1.136(a and the corresponding amount of the fee. atutory period for reply originally set in the	The appropriate extension fee under 37 final Office action; or (2) as set forth in (b)				
NOTICE OF APPEAL. 2. The reply was filed after the date of filing a Notice of Appeal, but prior to the date of filing an appeal brief. The Notice of Appeal was filed on 29 August 2005. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).						
<u>AMENDMENTS</u>	·					
3. The proposed amendment(s) filed after a final rejection, (a) They raise new issues that would require further co	onsideration and/or search (see NC					
 (b) ☐ They raise the issue of new matter (see NOTE below) (c) ☐ They are not deemed to place the application in beautiful appeal; and/or 		educing or simplifying the issues for				
(d)☐ They present additional claims without canceling a		ejected claims.				
NOTE: see attachment. (See 37 CFR 1.116 and	` ''					
4. The amendments are not in compliance with 37 CFR 1.1		ompliant Amendment (PTOL-324).				
5. Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling						
the non-allowable claim(s).						
7. For purposes of appeal, the proposed amendment(s): a) the new or amended claims would be rejected is provided. The status of the claim(s) is (or will be) as follows: Claim(s) allowed:		be entered and an explanation of how				
Claim(s) objected to: Claim(s) rejected: <u>1 and 23-25</u> .						
Claim(s) withdrawn from consideration: 4-7,10-22 and 26	5.					
AFFIDAVIT OR OTHER EVIDENCE						
8. The affidavit or other evidence filed after a final action, be because applicant failed to provide a showing of good an and was not earlier presented. See 37 CFR 1.116(e).						
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to a showing a good and sufficient reasons why it is necessar	overcome <u>all</u> rejections under appe y and was not earlier presented. S	al and/or appellant fails to provide a See 37 CFR 41.33(d)(1).				
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after e	entry is below or attached.				
11. The request for reconsideration has been considered bu see attachment.	it does NOT place the application i	n condition for allowance because:				
12. Note the attached Information Disclosure Statement(s). (PTO/SB/08 or PTO-1449) Paper No(s).						

13. Other: ____.

Irene Marx Primary Examiner Art Unit: 1651 Application/Control Number: 10/077,283

Art Unit: 1651

Note:

The proposed amendment raises new issues that would require further consideration and/or search with respect to the changes to the preamble and to the ingredients of claims 23-25, including new issues under 37 C.F.R. § 112 and of new matter. For example, there is no clear basis or support for the addition of calcium and manganese from Table 5 in preference to any of the other ingredients from this table which are not part of "a daily dosage" composition.

Response to Arguments

Applicant's arguments have been fully considered but they are not deemed to be persuasive. Regarding applicant's argument that basis for "A daily dosage of a composition" is found at page 5, lines 29-32, it is noted that this section of the specification broadly states:

"The daily intake of the metabolic compounds of the Krebs cycle is further enhanced by the addition of ascorbate, thiamine, riboflavin, certain minerals and trace elements and other cofactors for the enzymatic reaction in this cycle. Optimum supply of these coenzymes can compensate -at least in part- for the insufficient availability of the enzyme itself due to a genetic defect, e.g., fumarase deficiency."

The relevance of this statement to the invention as now claimed is not delineated with any particularity.

The further arguments are directed to claims that are not entered. Therefore, these arguments are not persuasive of error in the rejections.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Irene Marx whose telephone number is (571) 272-0919. The examiner can normally be reached on M-F (6:30-3:00).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

There niang. Irene Marx **Primary Examiner**

Art Unit 1651